Prior authorization criteria for vonoprazan (Potassium-competitive acid blocker)
Customize your policy alerts
Sign up for allcareadvantage Policy 126.1 alerts
Get alerted when Policy 126.1 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization criteria for coverage of the potassium-competitive acid blocker vonoprazan (Voquezna) for AllCare Advantage / AllCare CCO members, including indications for erosive esophagitis and H. pylori treatment, and renewal conditions.
No material clinical or coverage changes in this revision.
Coverage Criteria for Vonoprazan (Voquezna)
Initial Therapy
Covered when ALL of the following are met
Initial approval length: up to 6 months (see policy for specific durations per indication).
Renewal Therapy
Renewal covered when ALL of the following are met
Renewal approval length: up to 12 months; longer-term maintenance >6 months requires committee/MD review.
Vonoprazan is not FDA‑approved for pediatric use. Requests for members aged <18 years should be denied for lack of indication; the policy requires the patient to be 18 years or older for coverage consideration.
Proton‑pump inhibitors (PPIs) remain the first‑line therapy for most patients. Although vonoprazan has a faster onset and blocks both active and resting proton pumps, clinical evidence shows similar healing efficacy to PPIs for erosive esophagitis and no single PPI has superior healing; cost and comparable effectiveness support continuing PPIs as the preferred initial treatment.
Provider Requirements, Documentation, and Denial Triggers
Prior authorization must be by/with a gastroenterologist for adults
Prior authorization is required for vonoprazan and the request must be written by or in consultation with a gastroenterologist for adult members. Ensure the prescriber relationship and adult patient age are documented in the PA request.
Step therapy: failure/contraindication to 3 preferred PPIs required
Member must have documentation of failure of an adequate trial of — or a contraindication to — three preferred formulary proton‑pump inhibitors before approval for erosive esophagitis.
- Approval if documentation of failed/contraindicated trials of 3 preferred formulary PPIs (Approve x8 weeks).
- Deny if documentation of failure/contraindication to 3 preferred formulary PPIs is not provided.
Required documentation: diagnosis and prior trials/failures
Documentation submitted with the PA must support the diagnosis (erosive esophagitis or H. pylori infection) and must show prior PPI trials/failures or contraindications; for H. pylori treatment, include documentation of failure of at least one standard therapy. For renewals, provide objective documentation of prior criteria being met and treatment response or failure.
- Sufficient documentation of erosive esophagitis diagnosis or indication for H. pylori therapy.
- Records showing trials and outcomes for 3 preferred formulary PPIs or documented contraindications.
- For H. pylori: documentation of inadequate response to at least one standard therapy.
- For renewals: objective documentation of treatment response or failure and evidence that initial criteria were met.
Denial triggers: prescriber, age, and insufficient documentation
Requests will be denied if the prescriber is not a gastroenterologist (or the request is not in consultation with one), if the member is under 18 years of age, or if documentation is insufficient to support the diagnosis or required prior trials/failures/contraindications.
- Prescriber not a gastroenterologist and no documented consultation — Deny.
- Member age <18 years (vonoprazan not FDA‑approved for pediatric use) — Deny.
- Insufficient documentation of erosive esophagitis or H. pylori diagnosis — Deny.
- Missing documentation of trials/contraindications to 3 preferred formulary PPIs or lack of documented failed standard H. pylori therapy — Deny.
Background on Vonoprazan and Indications
Vonoprazan (a potassium‑competitive acid blocker, PCAB) is FDA‑approved in adults for healing of all grades of erosive esophagitis, maintenance of healed erosive esophagitis, and for use in combination regimens to treat Helicobacter pylori (H. pylori) infection. It blocks both active and resting proton pumps, has a faster onset of action than PPIs, and may be taken with or without food; however, overall efficacy for healing erosive esophagitis is similar to that of PPIs.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.